Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry
Table 1
Clinical and demographic characteristics of the study cohort.
Assessed in-person
Not assessed in-person
Combined cohort
valuea
MDS-UPDRS Part III, mean (SD)
37.0 (18.0)
N/A
N/A
N/A
Hoehn and Yahr scale score median (range)
2 (1–5)
N/A
N/A
N/A
Mean (SD)
2.5 (0.9)
Bradykinesia, (%)
77 (100)
29 (100)
106 (100)
1.0b
Rigidity, (%)
73 (94.8)
29 (100)
102 (96.2)
0.57b
Resting tremor, (%)
51 (66.2)
24 (82.8)
75 (70.8)
0.15b
Postural instability, (%)
30 (39.0)
19 (65.5)
49 (46.2)
0.02b
Male, (%)
59 (76.6)
20 (69.0)
79 (74.5)
0.46b
Disease duration, mean (SD)
11.0 (7.5)
10.7 (7.3)
10.9 (7.4)
0.89c
Age at assessment, mean (SD)
69.7 (8.4)
66.6 (12.3)
68.8 (9.6)
0.15c
Duration between enrollment and assessment (years), Mean (SD)d
2.7 (1.0)
N/A
N/A
N/A
aComparing patients in the “assessed in-person” and “not assessed in-person” groups; bFisher’s exact test; cunpaired t-test; dcalculated only for “assessed in-person” group since data ascertained for the “not assessed in-person” group was sometimes derived from clinical or research visits that occurred before enrollment in the WPDR validation study.